Goldman Sachs Group Inc Rallybio Corp Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Rallybio Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 181,202 shares of RLYB stock, worth $201,134. This represents 0.0% of its overall portfolio holdings.
Number of Shares
181,202
Previous 13,243
1268.29%
Holding current value
$201,134
Previous $24,000
908.33%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RLYB
# of Institutions
68Shares Held
32.2MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$4.66 Million0.02% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$4.04 Million1.68% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$4.03 Million2.28% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$3.66 Million5.39% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$3.36 Million0.1% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $35.7M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...